SCHEDULE 13D/A: Vedanta Partners Reduces Reviva Pharma Stake Below 5%

Vedanta Partners, LLC has reduced its beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. to below 5%, while Parag Saxena maintains a 5.2% stake.

Summary

• Vedanta Partners, LLC and Parag Saxena filed Amendment No. 12 to Schedule 13D regarding their beneficial ownership of Reviva Pharmaceuticals Holdings, Inc. common stock.
• Vedanta Partners, LLC ceased to be a beneficial holder of more than 5% of the Issuer's Common Stock on December 18, 2025, now holding 4.4% (5,367,069 shares).
• Parag Saxena beneficially owns 5.2% (6,268,006 shares) of the outstanding Common Stock as of December 22, 2025.
• Vedanta Partners' holdings include shares, warrants, and pre-funded warrants held by Vedanta Associates-R, Beta Operators Fund, Vedanta Associates, and Vedanta R2 Partners.
• Mr. Saxena's holdings include shares held directly, shares held by the Vedanta entities, and 29,600 fully vested options.
• Both reporting persons' beneficial ownership calculations exclude certain shares issuable upon warrant exercise due to a 4.99% issuance limitation.
• Mr. Saxena was granted 8,200 options to purchase Common Stock on December 18, 2025, in connection with his service as a director.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to Vedanta Partners, LLC reducing its stake below the 5% threshold, which can be interpreted as a reduced institutional commitment. However, this is partially offset by Mr. Saxena's continued significant ownership and receipt of new options, indicating ongoing individual involvement.

Positives

• Parag Saxena, a director, maintains a significant beneficial ownership of 5.2%, indicating continued alignment with shareholder interests.
• Mr. Saxena received an additional grant of 8,200 options on December 18, 2025, for his service as a director, reinforcing his commitment to the company.

Negatives

• Vedanta Partners, LLC, a significant institutional investor, reduced its beneficial ownership to 4.4%, falling below the 5% threshold, which could be perceived as a decrease in conviction or a portfolio rebalancing.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing primarily concerns changes in beneficial ownership by specific investors and does not provide broader insights into industry trends or competitive landscape.

Related Party Transactions

• Mr. Saxena, a director of the Issuer, was granted 8,200 options to purchase Common Stock on December 18, 2025, as compensation for his service.

Stakeholder Impact

• Shareholders may react to the reduction in institutional ownership by Vedanta Partners, potentially influencing market perception and trading activity.
• The continued significant ownership and option grant to Mr. Saxena may reassure investors of management's ongoing commitment.

Key Dates

Recommendation

The reduction in Vedanta Partners' beneficial ownership below 5% could be viewed as a minor negative signal, potentially indicating a shift in institutional investment strategy. However, Mr. Saxena, a director, maintains a substantial 5.2% stake and received new options, suggesting continued personal commitment. Without additional operational or strategic news, the information presented in this ownership update is not compelling enough to warrant a strong buy or sell recommendation, thus a 'hold' position is appropriate for a seasoned investor.

Keywords

Reviva Pharmaceuticals, Vedanta Partners, Parag Saxena, Schedule 13D, beneficial ownership, common stock, warrants, pre-funded warrants, options